Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells

Blood

Volumn 98, Issue 13, 2001, Pages 3864-3867

  Tipping, Alex J ^a,b   Manon, François X ^a,b   Lagarde, Valerie ^a,b   Goldman, John M ^a,b   Melo, Junia V ^a,b,c  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

EID: 0035895106     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.13.3864     Document Type: Article

References (11)

1. Goldman JM. Treatment of chronic myeloid leukaemia: some topical questions. Baillieres Clin Haematol. 1997;10:405-421.
2. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
3. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
4. Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96:1070-1079.
5. Drexler HG. The Leukemia-Lymphoma Cell Line Facts Book. London, United Kingdom: Academic Press; 2000.
6. Deininger MWN, Goldman JM, Lydon NB, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood. 1997;90:3691-3698.
7. Strasser A, Harris AW, Huang DC, Krammer PH, Cory S. Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J. 1995;14:6136-6147.
8. Melo JV, Gordon DE, Cross NC, Goldman JM. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood. 1993;81:158-165.
9. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7:228-234.
10. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
11. Talpaz M, Donato NJ, Wu JY, Sah NK, Kantarjian H. Characterization of the clinical response to STI571: biochemical evaluation of response and resistant advanced stage chronic myelogenous leukemia patients [abstract]. Blood 2000;96:735a.